Clinical experience with MK-571. A potent and specific LTD4 receptor antagonist.
Margolskee
D J
DJ
Merck, Sharp & Dohme Research Laboratories, Rahway, New Jersey 07063.
D001249:Asthma / Q000188:drug therapy*; D001250:Asthma, Exercise-Induced / Q000188:drug therapy*; D006801:Humans; D008168:Lung / Q000187:drug effects / Q000502:physiology / Q000503:physiopathology*; D011422:Propionates / Q000494:pharmacology / Q000627:therapeutic use*; D011804:Quinolines / Q000494:pharmacology / Q000627:therapeutic use*; D011971:Receptors, Immunologic / Q000037:antagonists & inhibitors*; D018077:Receptors, Leukotriene; D013189:SRS-A / Q000037:antagonists & inhibitors*
D011422:Propionates; D011804:Quinolines; D011971:Receptors, Immunologic; D018077:Receptors, Leukotriene; D013189:SRS-A; C059141:verlukast